Independent
Tenure on this board
5.7 yrs
Also a director at
Biogen Inc (BIIB)Mimedx Group Inc (MDXG)
Meeting calendar
BVS · Annual meeting · Wednesday, June 3, 2026
Bioventus Inc
12 nominees · 2 ballot items.
Election of twelve (12) directors nominated by the Board to serve until the 2027 Annual Meeting; Ratification of Grant Thornton LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2026.
Market cap
$1.1B
1Y TSR
+96.2%
Board grade
B
Record date
Apr 6, 2026
Filing
DEF 14A
Meeting concluded · Jun 3, 2026
Follow how the vote landed and what changed on Bioventus Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of the twelve (12) directors nominated by the Board
ManagementBoard: FORElect twelve directors nominated by the Board to serve until the 2027 Annual Meeting and until their successors are duly elected and qualified.
- 2
Ratification of Appointment of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
Director elections
Nominees on the ballot12
Independent
Tenure on this board
3.8 yrs
Also a director at
Lincoln Educational Services Corp (LINC)
Independent
Tenure on this board
5.0 yrs
Also a director at
Conmed Corp (CNMD)
Not independent
Tenure on this board
2.8 yrs
Independent
Tenure on this board
5.7 yrs
Independent
Tenure on this board
0.9 yrs
Independent
Tenure on this board
5.3 yrs
Also a director at
Inogen Inc (INGN)Novanta Inc (NOVT)Kestra Medical Technologies Ltd (KMTS)
Independent
Tenure on this board
4.8 yrs
Also a director at
Revvity Inc (RVTY)
Independent
Tenure on this board
5.7 yrs
Also a director at
Elutia Inc (ELUT)Tela Bio Inc (TELA)
Independent
Tenure on this board
5.7 yrs
Also a director at
Tela Bio Inc (TELA)
Independent
Tenure on this board
5.7 yrs
Independent
Tenure on this board
5.7 yrs
Also a director at
Mimedx Group Inc (MDXG)
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Essex Woodlands Management, Inc. | 15.5% | 13,021,324 | $123M |
| 2 | Juniper Investment Company, LLC | 8.3% | 6,939,357 | $66M |
| 3 | Nantahala Capital Management, LLC | 7.1% | 6,000,279 | $57M |
| 4 | BlackRock, Inc. | 2.3% | 1,965,445 | $19M |
| 5 | ROYCE & ASSOCIATES LP | 2.2% | 1,833,212 | $17M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 2.1% | 1,751,678 | $17M |
| 7 | AMERICAN CENTURY COMPANIES INC | 1.6% | 1,353,415 | $13M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 1,192,161 | $11M |
| 9 | BlackRock, Inc. | 1.4% | 1,168,968 | $11M |
| 10 | STATE STREET CORP | 1.3% | 1,104,878 | $10M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Bioventus Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Varex Imaging CorpVREX
Special meeting·Oct 28, 2026·$774M
Phibro Animal Health CorpPAHC
Annual meeting·Nov 3, 2026·$1.5B
Wave Life Sciences IncWVE
Annual meeting·Nov 12, 2026·$609M
Weave Communications IncWEAV
Special meeting·Oct 22, 2026·$591M
Angiodynamics IncANGO
Annual meeting·Nov 17, 2026·$465M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$464M
Reference
Frequently asked questions
- When is the Bioventus Inc 2026 annual meeting?
- Bioventus Inc (BVS) holds its 2026 annual shareholder meeting on Wednesday, June 3, 2026.
- What is the record date for the Bioventus Inc 2026 meeting?
- The record date for the Bioventus Inc 2026 meeting is Monday, April 6, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Bioventus Inc's 2026 meeting?
- The board is presenting 12 director nominees at the Bioventus Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Bioventus Inc 2026 meeting?
- Shareholders will vote on 2 proposals at the Bioventus Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.